Cobicistat
Back to searchMolecule Structure
Scientific Name
Cobicistat
Description of the Drug
Cobicistat is a CYP3A inhibitor used to increase the systemic exposure of atazanavir or darunavir in combination with other antiretroviral agents in the treatment of HIV-1 infection.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB09065
http://www.drugbank.ca/drugs/DB09065
Brand Name(s)
Tybost
Company Owner(s)
Bristol-Myers Squibb Co, Janssen Products Lp, Gilead Sciences Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Cytochrome P450 3A | PROTEIN FAMILY | INHIBITOR | CHEMBL2364675 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL2736227 | |
| PharmGKB | PA166165092 | |
| DrugBank | DB09065 | |
| PubChem: Thomson Pharma | 57245301 | |
| PubChem | 25151504 | |
| LINCS | LSM-45771 | |
| Nikkaji | J3.033.505H | |
| BindingDB | 50447471 | |
| EPA CompTox Dashboard | DTXSID00143269 | |
| DrugCentral | 4299 | |
| ChemicalBook | CB62627692 | |
| Guide to Pharmacology | 7535 | |
| rxnorm | TYBOST | COBICISTAT |
| ChEBI | 72291 | |
| ZINC | ZINC000085537014 |
